Preparing for first-in-man studies: the challenges for translational immunology post-TGN1412
- 7 January 2008
- journal article
- review article
- Published by Oxford University Press (OUP) in Clinical and Experimental Immunology
- Vol. 151 (2) , 231-234
- https://doi.org/10.1111/j.1365-2249.2007.03559.x
Abstract
Current immunology research is generating many new approaches to immunotherapy. However, the recent disaster surrounding the testing of TGN1412, has unsettled regulators and the pharmaceutical industry regarding new immunotherapies and highlighted the complexities of conducting clinical trials with agents that target the immune system. Here we discuss the critical role for immunologists in ensuring that the development of new immunotherapies continues.Keywords
This publication has 9 references indexed in Scilit:
- The Northwick Park tragedy ? protecting healthy volunteers in future first-in-man trialsJournal of Clinical Pharmacy & Therapeutics, 2007
- Some aspects of the recombinantly expressed humanised superagonist anti-CD28 mAb, TGN1412 trial catastrophe lessons to safeguard mAbs and vaccine trialsVaccine, 2007
- Critics pan timid European response to TeGenero disasterNature Biotechnology, 2007
- A personal perspective on the Royal Statistical Society report of the working party on statistical issues in first‐in‐man studiesPharmaceutical Statistics, 2007
- “We saw human guinea pigs explode”BMJ, 2007
- Establishing risk of human experimentation with drugs: lessons from TGN1412The Lancet, 2006
- Cytokine Storm in a Phase 1 Trial of the Anti-CD28 Monoclonal Antibody TGN1412New England Journal of Medicine, 2006
- Evaluation of Patients Treated with Natalizumab for Progressive Multifocal LeukoencephalopathyNew England Journal of Medicine, 2006
- Insulin Needs after CD3-Antibody Therapy in New-Onset Type 1 DiabetesNew England Journal of Medicine, 2005